Released Nov 6, 2013, after the close
10-Q filed Nov 6, 2013, 37 days after period end · 0001390478-13-000031
Q3 2013 · 10-Q
Revenue$2.17M$2.17M ±0.0% vs Q3 2012−36.0% vs Q2 2013
Net Income-$6.93M-$6.93M N/M vs Q3 2012N/M vs Q2 2013
EPS Diluted-$0.11-$0.11 N/M vs Q3 2012N/M vs Q2 2013
Gross Profit$1,454,000±0.0%
Operating Income-$6,893,000N/M
Operating Cash Flowderived-$7,983,000N/M
Free Cash Flowderived-$8,087,000—
Margins · derived
Gross margin67.1%±0.0 pt vs Q3 2012
Operating margin-318.2%−63.0 pt vs Q3 2012
Net margin-319.9%+512.3 pt vs Q3 2012
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2013 | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|---|
| Revenue | $2.17M | $2.17M | — | — |
| Net Income | -$6.93M | -$18.03M | -$5.48M | -$4.14M |
| EPS Diluted | -$0.11 | -$0.09 | -$0.14 | -$0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR